ArticleArteriosclerosis, thrombosis, and vascular biology2022
Angiopoietin-2: An Emerging Tie to Pathological Vessel Enlargement.
Article in Arteriosclerosis, thrombosis, and vascular biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Article
- Circulating angiopoietin-2 and TEK receptor tyrosine kinase-2 protein provide prognostic value in patients with acute myocardial infarction.BMC cardiovascular disorders · 2026Article
- Qideng Mingmu Capsules Ameliorates Retinal Neovascularization by Regulating Ang/Tie2 Signaling Pathway.Chinese journal of integrative medicine · 2026Article
- [Correlation of Serum Neuron-Specific Enolase, Angiopoietin-1, and Angiopoietin-Like Protein-3 With Disease Severity and Their Prognostic Value in Patients With Cerebral Infarction].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025Article
- PKM2 regulates angiogenic activation via ANGPT2 in endothelial cells.Scientific reports · 2025Article
- Angiopoietins: multifaceted mediators in the pathogenesis of joint-related disorders.Histochemistry and cell biology · 2025Review
- Defining the Role of Oral Pathway Inhibitors as Targeted Therapeutics in Arteriovenous Malformation Care.Biomedicines · 2024Review
Corrections and comments
- Comment onEndothelial2022
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
34758631What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.